Concepedia
Statistics
Publications
9
Citations
314
H-Index
Active since
2012
Affiliations
Regeneron (United States)(Current)
Universitat Autònoma de Barcelona
Catholic University of Korea
Mayo Clinic in Arizona
The University of Melbourne
Melanie Ufkin is an author at Regeneron (United States) specializing in medicine, oncology, and immunotherapy.
Publications per year
2012–2025
miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia
Melanie Ufkin, Sarah Peterson, Xuehui Yang et al. · Leukemia Research · 2014 · 77 citations
Life Sciences, Molecular Biology, Oncology +16
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Rajat Bannerji, John N. Allan, Jon Arnason et al. · Blood · 2019 · 57 citations
Medicine, Hematology, Oncology +17
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Sabarish Ayyappan, Won Seog Kim, Tae Min Kim et al. · Blood · 2023 · 48 citations
Medicine, Oncology, Pharmacotherapy +12
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Won Seog Kim, Tae Min Kim, Seok‐Goo Cho et al. · Nature Cancer · 2025 · 44 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +17
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Won-Seog Kim, Tae Min Kim, Seok‐Goo Cho et al. · Blood · 2022 · 28 citations
1–5 of 9